Strides Pharma to monetise stake in Pivot Path; company valued at ₹230 crore post

Strides Pharma Science will monetise its stake in Pivot Path Private Limited, valued at ₹230 crore post-money. Ascent Capital led the transaction, with Vintage Classic as co-investor. Strides got near ₹100 crore and will keep a 20% stake. Pivot Path also received ₹50 crore capital infusion.